Araújo A, Et Al. An Economic Analysis of Erlotinib, Docetaxel, Pemetrexed and Best Supportive Care as Second or Third Line Treatment of Non-Small Cell Lung Cancer Rev Port Pneumol 2008; 14(6):803–827
AuthID
P-00H-GST
P-00H-GST